Janssen-developed clinical trials tech available for industry use

By Melissa Fassbender contact

- Last updated on GMT

Janssen Research & Development collaborated with Tata Consultancy Services (TCS) to build out the clinical trials platform. (Image: iStock/utah778)
Janssen Research & Development collaborated with Tata Consultancy Services (TCS) to build out the clinical trials platform. (Image: iStock/utah778)
The new Software as a Service (SaaS) solution provides tools for clinical trials medication management and patient engagement.

The new platform features four modules including, communication, adherence, label, and tracking

The approach was developed by Janssen Research & Development as part of its integrated Smart Trial and Engagement Platform (iSTEP) initiative and will be made available for industry-use via Tata Consultancy Services (TCS) under the name Connected Clinical Trials (CCT).

Drug accountability and medication management are the most complex elements of a clinical trial. CCT automates this entire process and thereby removes guesswork from the clinical trial​,” a TCS spokesperson told Outsourcing-Pharma.com.

Moreover, CCT leverages a powerful device data acquisition and analytical framework that helps a clinical trial benefit from a variety of devices on a single platform. Each trial is unique in itself and CCT helps study teams flexibly manage variation across trials through extensive configuration capability​.”

The platform has been tested and proven in a live set-up at TCS' User Experience labs with global patient and site advisory boards in collaboration with the Center for Information and Study on Clinical Research Participation (CISCRP).

Additionally, Janssen has conducted a technical pilot and is working with health authorities and ethics committees to implement a pilot assessment of the technology in a clinical trial by the end of 2017.

Janssen plans to gradually implement iSTEP into clinical trials in its portfolio, according to the company.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers